Please assess the completion status of the following clinical trial:

Trial Title: Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be considered eligible for enrolment into the study, subjects must;~1. Be able to give written informed consent,~2. Be between 18 and 75 years of age,~3. Be in generally good health as determined by the investigator OR have mild gastrointestinal discomfort, such as mild indigestion,~4. Have a positive urease breath test (\> 1.5)~Exclusion Criteria:~Subjects will be excluded from the study if they meet any of the below criteria;~1. Are less than 18 and greater than 75 years of age,~2. Females are pregnant, lactating or wish to become pregnant during the study.~3. Are hypersensitive to any of the components of the test product,~4. Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study,~5. Have an active gastrointestinal disorder or previous gastrointestinal surgery,~6. Having a condition or have taken a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include proton pump inhibitors or gastroprotective medicines,~7. Have taking antibiotics in the past 3 months,~8. Prior eradication therapy with antibiotics for H. pylori infection,~9. Have not made any major dietary changes in the past 3 months,~10. Are taking non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks of baseline visit or for the duration of the trial,~11. History of illicit drug use,~12. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial,~13. Subjects may not be receiving treatment involving experimental drugs,~14. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study,~15. Have a malignant disease or any concomitant end-stage organ disease,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - 2 doses per day for 4 weeks
- Pylopass (Type: ACTIVE_COMPARATOR): Probiotic - 2 doses per day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).